Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.62 |
| ▸ | OXTR | P30559 | 3/20 | 0.62 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598108 | 1.00 | POLB (0.70) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL27197579 | 0.93 | POLB (0.70) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL29598193 | 0.93 | POLB (0.70) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL24499976 | 0.90 | POLB (0.80) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL29597092 | 0.90 | POLB (0.80) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL27197599 | 0.89 | POLB (0.64) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL29598005 | 0.89 | POLB (0.64) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL24499960 | 0.87 | POLB (0.62) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL24499929 | 0.87 | POLB (0.61) | POLBHSD17B10AVPR2OXTRAVPR1A | |
| SCHEMBL29597660 | 0.87 | POLB (0.61) | POLBHSD17B10AVPR2OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124431-A1 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | ORION CORPORATION (FI) | 2024-04-18 | — | — | US | claimed |
| US-20240124431-A1 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | ORION CORPORATION (FI) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124431-A1 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | CYP11B1, CYP11B2, SRD5A1 | POLB 1415/4885HSD17B10 61/4885AVPR2 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.